CNS Pharmaceuticals (CNSP) Profit After Tax (2018 - 2025)

CNS Pharmaceuticals (CNSP) has 8 years of Profit After Tax data on file, last reported at -$6.0 million in Q4 2025.

• Quarterly Profit After Tax fell 87.5% year-over-year to -$6.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.9 million (down 6.68% YoY) and the FY2025 annual result came in at -$15.9 million, down 6.68% from the prior year.
• Profit After Tax slipped to -$6.0 million in Q4 2025, from -$3.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$2.4 million in Q2 2025 to a low of -$6.0 million in Q4 2025.
• A 5-year average of -$4.0 million and a median of -$3.7 million in 2021 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2021 — Profit After Tax slumped 89.67% — and 2025, when it soared 42.59%.
• Tracing CNSP's Profit After Tax over 5 years: stood at -$3.3 million in 2021, then tumbled by 57.87% to -$5.1 million in 2022, then dropped by 4.64% to -$5.4 million in 2023, then jumped by 40.91% to -$3.2 million in 2024, then tumbled by 87.5% to -$6.0 million in 2025.
• The last three Profit After Tax figures came in at -$6.0 million (Q4 2025), -$3.2 million (Q3 2025), and -$2.4 million (Q2 2025), per Business Quant data.